



**Supplementary figure S2.**  
Trough ivoxolimab concentration ( $C_{trough}$ ) vs. immunogenicity.

**A**



**B**



Trough ivoxolimab concentration ( $C_{trough}$ ) vs. immunogenicity plots. The dashed line represents LLOQ (20.0 ng/mL). All  $C_{trough}$  below LLOQ have been assigned the value of 10 ng/mL for purpose of visualization. **A**,  $C_{trough}$  vs. immunogenicity status (ADA-, ADA+/NAb-, or ADA+/NAb+) by dose group. All immunogenicity and the companion  $C_{trough}$  data up to week 16 from the 0.1, 0.3, and 1.5 mg/kg dose groups were included. For ADA+ samples, the size of the symbols corresponds to the  $\log_{10}$  of ADA titer by quartiles. **B**,  $C_{trough}$ , ADA, and NAb titers vs. time profiles for selected patients (blue= $C_{trough}$ ; orange= $\log_{10} ADA_{titer}$ ; red= $\log_{10} NAb_{titer}$ ). Patients 1 and 2 (top panels) represent typical patients (from the 0.1 mg/kg dose level) whose isolated and low ADA responses (with NAb-) had no effect on ivoxolimab PK. Patients 3 and 4 (bottom panels) are the two patients (both at the 0.1 mg/kg dose level) who had sustained high NAb titers ( $\log_{10}$  of NAb titer >0.5) also had lower  $C_{trough}$  compared with the expected profiles.

ADA, anti-drug antibody;  $C_{trough}$ , maximum concentration at trough; NAb, neutralizing antibody; PK, pharmacokinetics